Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II

This article was originally published in The Pink Sheet Daily

Executive Summary

New unit could help better coordinate policy, operations and other biosimilar functions, FDA tells industry.

Advertisement

Related Content

Biosimilar Guidance Development Timelines Criticized By Docs And Patients
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges
FDA Generics Office Drinks Super Serum, Then Shrinks

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register